An extension to the current UK approval of the Spikevax vaccine (formerly COVID-19 Vaccine Moderna) that allows its use in 12- to 17-year-olds has today been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA). This Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in Great Britain only and was approved